Serum IL-1<mml:math alttext="$\beta $" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math>, IL-2, and IL-6 in Insulin-Dependent Diabetic Children

Dogan, Yasar; Akarsu, Saadet; Ustundag, Bilal; Yilmaz, Erdal; Gurgoze, Metin Kaya

doi:https://doi.org/10.1155/MI/2006/59206

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Communication | Open Access

Volume 2006 | Article ID 059206 | https://doi.org/10.1155/MI/2006/59206

Serum IL-1β, IL-2, and IL-6 in Insulin-Dependent Diabetic Children

Yasar Dogan,¹Saadet Akarsu,¹Bilal Ustundag,²Erdal Yilmaz,¹and Metin Kaya Gurgoze¹

Received10 Jul 2005

Accepted28 Oct 2005

Published01 Feb 2006

Abstract

Insulin-dependent diabetes mellitus (IDDM) is a chronic disease characterized by T-cell-dependent autoimmune destruction of the insulin-producing β cells in the pancreatic islets of Langerhans, resulting in an absolute lack of insulin. T cells are activated in response to islet-dominant autoantigens, the result being the development of IDDM. Insulin is one of the islet autoantigens responsible for the activation of T-lymphocyte functions, inflammatory cytokine production, and development of IDDM. The aim of this study was to investigate serum concentrations of interleukin (IL)-1β, IL-2, IL-6, and tumor necrosis factor (TNF)-α in children IDDM. The study population consisted of 27 children with IDDM and 25 healthy controls. Children with IDDM were divided into three subgroups: (1) previously diagnosed patients (long standing IDDM) (n:15), (2) newly diagnosed patients with diabetic ketoacidosis (before treatment) (n:12), and (3) newly diagnosed patients with diabetic ketoacidosis (after treatment for two weeks) (n:12). In all stages of diabetes higher levels of IL-1β and TNF-α and lower levels of IL-2 and IL-6 were detected. Our data about elevated serum IL-1β, TNF-α and decreased IL-2, IL-6 levels in newly diagnosed IDDM patients in comparison with longer standing cases supports an activation of systemic inflammatory process during early phases of IDDM which may be indicative of an ongoing β-cell destruction. Persistence of significant difference between the cases with IDDM monitored for a long time and controls in terms of IL-1β, IL-2, IL-6, and TNF-α supports continuous activation during the late stages of diabetes.

References

A Kukreja, G Cost, J Marker et al., “Multiple immuno-regulatory defects in type-1 diabetes,” The Journal of Clinical Investigation, vol. 109, no. 1, pp. 131–140, 2002.
View at: Google Scholar
M G Karlsson Faresjo, J Ernerudh, and J Ludvigsson, “Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes,” Scandinavian Journal of Immunology, vol. 59, no. 5, pp. 517–526, 2004.
View at: Google Scholar
M J Hussain, J Maher, T Warnock, A Vats, M Peakman, and D Vergani, “Cytokine overproduction in healthy first degree relatives of patients with IDDM,” Diabetologia, vol. 41, no. 3, pp. 343–349, 1998.
View at: Google Scholar
A B Erbagci, M Tarakcioglu, Y Coskun, E Sivasli, and E Sibel Namiduru, “Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children,” Clinical Biochemistry, vol. 34, no. 8, pp. 645–650, 2001.
View at: Google Scholar
D L Eizirik, S Sandler, N Welsh et al., “Cytokines suppress human islet function irrespective of their effects on nitric oxide generation,” The Journal of Clinical Investigation, vol. 93, no. 5, pp. 1968–1974, 1994.
View at: Google Scholar
H Tchorzewski, E Glowacka, M Banasik, P Lewkowicz, and M Szalapska-Zawodniak, “Activated T lymphocytes from patients with high risk of type I diabetes mellitus have different ability to produce interferon-gamma, interleukin-6 and interleukin-10 and undergo anti-CD95 induced apoptosis after insulin stimulation,” Immunology Letters, vol. 75, no. 3, pp. 225–234, 2001.
View at: Google Scholar
M J Rapoport, A Mor, P Vardi et al., “Decreased secretion of Th2 cytokines precedes Up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus,” Journal of Autoimmunity, vol. 11, no. 6, pp. 635–642, 1998.
View at: Google Scholar
A El-Nawawy, T Soliman, O El-Azzouni et al., “Interleukin-1-beta, tumor necrosis factor-alpha, insulin secretion and oral glucose tolerance in non-diabetic siblings of children with IDDM,” Indian Journal of Pediatrics, vol. 65, no. 3, pp. 455–460, 1998.
View at: Google Scholar
M G Netea, N Hancu, W L Blok et al., “Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals,” Cytokine, vol. 9, no. 4, pp. 284–287, 1997.
View at: Google Scholar
G Ozer, Z Teker, S Cetiner et al., “Serum IL-1, IL-2, TNF-alpha and INF-gamma levels of patients with type 1 diabetes mellitus and their siblings,” Journal of Pediatric Endocrinology & Metabolism, vol. 16, no. 2, pp. 203–210, 2003.
View at: Google Scholar
A Rabinovitch and W L Suarez-Pinzon, “Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus,” Biochemical Pharmacology, vol. 55, no. 8, pp. 1139–1149, 1998.
View at: Google Scholar
G Davi, F Chiarelli, F Santilli et al., “Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration,” Circulation, vol. 107, no. 25, pp. 3199–3203, 2003.
View at: Google Scholar
G Targher, L Zenari, L Bertolini, M Muggeo, and G Zoppini, “Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications,” Diabetes Care, vol. 24, no. 5, pp. 956–957, 2001.
View at: Google Scholar
B Kulseng, G Skjak-Braek, I Folling, and T Espevik, “TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide,” Scandinavian Journal of Immunology, vol. 43, no. 3, pp. 335–340, 1996.
View at: Google Scholar
S E Geerlings, E C Brouwer, K C Van Kessel, W Gaastra, R P Stolk, and A I Hoepelman, “Cytokine secretion is impaired in women with diabetes mellitus,” European Journal of Clinical Investigation, vol. 30, no. 11, pp. 995–1001, 2000.
View at: Google Scholar
J C Pickup, G D Chusney, S M Thomas, and D Burt, “Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes,” Life Sciences, vol. 67, no. 3, pp. 291–300, 2000.
View at: Google Scholar
P Peraldi and B Spiegelman, “TNF-alpha and insulin resistance: summary and future prospects,” Molecular and Cellular Biochemistry, vol. 182, no. 1-2, pp. 169–175, 1998.
View at: Google Scholar
M I Schmidt, B B Duncan, A R Sharrett et al., “Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study,” Lancet, vol. 353, no. 9165, pp. 1649–1652, 1999.
View at: Google Scholar
C C Gerhardt, I A Romero, R Cancello, L Camoin, and A D Strosberg, “Chemokines control fat accumulation and leptin secretion by cultured human adipocytes,” Molecular and Cellular Endocrinology, vol. 175, no. 1-2, pp. 81–92, 2001.
View at: Google Scholar
J L Wautier, C Zoukourian, O Chappey et al., “Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats,” The Journal of Clinical Investigation, vol. 97, no. 1, pp. 238–243, 1996.
View at: Google Scholar
A M Schmidt, O Hori, R Cao et al., “RAGE: a novel cellular receptor for advanced glycation end products,” Diabetes, vol. 45, no. suppl 3, pp. S77–S80, 1996.
View at: Google Scholar
T Tomoda, T Kurashige, and T Taniguchi, “Imbalance of the interleukin 2 system in children with IDDM,” Diabetologia, vol. 37, no. 5, pp. 476–482, 1994.
View at: Google Scholar
W A Kaye, M N Adri, J S Soeldner et al., “Acquired defect in interleukin-2 production in patients with type I diabetes mellitus,” The New England Journal of Medicine, vol. 315, no. 15, pp. 920–924, 1986.
View at: Google Scholar
R Lorini, D Montagna, A Lanfranchi et al., “Alterations of in vitro interleukin 1 and 2 in diabetic children,” European Journal of Pediatrics, vol. 148, no. 8, pp. 732–734, 1989.
View at: Google Scholar
W Huang, D S Wang, X Y Li, W Z Wu, and G C Ni, “Expression levels of IL-6 mRNA in PBMNCs from patients with IDDM, NIDDM and normals by RT-PCR procedure,” Chinese Medical Journal, vol. 106, no. 12, pp. 893–897, 1993.
View at: Google Scholar
U Shah, L Karch, L Baker, and K S Zier, “Low interleukin-2 synthesis by type 1 diabetics is regulated at the pretranslational level,” Clinical Immunology and Immunopathology, vol. 61, no. 2 pt 1, pp. 177–190, 1991.
View at: Google Scholar
M G Roncarolo, M Zoppo, R Bacchetta et al., “Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes,” Clinical Immunology and Immunopathology, vol. 49, no. 1, pp. 53–62, 1988.
View at: Google Scholar
A Kretowski, J Mysliwiec, M Szelachowska, C Brzozowski, M Pietruczuk, and I Kinalska, “In vitro secretion of interleukin 2 and expression of IL-2 receptor in peripheral blood lymphocytes in high risk of insulin-dependent diabetes mellitus subjects,” Archivum Immunologiae et Therapiae Experimentalis, vol. 47, no. 1, pp. 45–49, 1999.
View at: Google Scholar
R Wagner, E Bonifacio, P J Bingley, S Genovese, D Reinwein, and G F Bottazzo, “Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes,” The Clinical Investigator, vol. 72, no. 7, pp. 494–498, 1994.
View at: Google Scholar
L A Gartner, M C Pfeifer, C Albini, and G L Francis, “Soluble interleukin 2 receptor levels in children with type I insulin-dependent diabetes mellitus,” Annals of Clinical and Laboratory Science, vol. 25, no. 1, pp. 44–51, 1995.
View at: Google Scholar
K S Zier, M M Leo, R S Spielman, and L Baker, “Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus,” Diabetes, vol. 33, no. 6, pp. 552–555, 1984.
View at: Google Scholar
A Wedrychowicz, H Dziatkowiak, K Sztefko, and A Wedrychowicz, “Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus,” Experimental and Clinical Endocrinology & Diabetes, vol. 112, no. 8, pp. 435–439, 2004.
View at: Google Scholar
S K Jain, K Kannan, G Lim, J Matthews-Greer, R McVie, and J A Jr Bocchini, “Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes,” Diabetes Care, vol. 26, no. 7, pp. 2139–2143, 2003.
View at: Google Scholar

Copyright

Copyright © 2006 Yasar Dogan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

896

Downloads

1479

Citations